This short document provides a link to more information about deadlift dynamite on the valuesponsors.com website. Clicking the link would take the user to a page with additional details about deadlift exercises or related products/services. In a few words, it directs the reader to learn more about deadlifts online.
This document discusses bone structure and repair. It describes how bone defects like fractures require repair through tissue engineering approaches using mesenchymal stem cells (MSCs). While MSC therapy shows promise in preclinical studies, it faces challenges in clinical translation due to regulatory hurdles, remaining scientific problems, and high costs. The document also explores how implanted MSCs may trigger endogenous bone repair by stimulating macrophage migration, angiogenesis, and new bone formation. Finally, it outlines research objectives to further study the effects of microenvironments like hypoxia and inflammation on MSC paracrine activity and develop products from platelets and MSC-conditioned media for tissue repair.
The Molecular Biotechnology Center (MBC) is a research center located at the University of Torino that brings together investigators from different scientific backgrounds to facilitate interdisciplinary biomedical research. The MBC has over 200 researchers working in 6 main areas: inflammatory diseases, oncogenesis and tumor immunology, cardiac hypertrophy, stem cells, neurobiology, and bioinformatics. It provides facilities like an animal house, transgenic mouse generation, protein production, and antibody characterization to support the research.
This document describes the facilities and research at ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), a transplant hospital and research foundation in Palermo, Italy. The document outlines ISMETT's laboratories for regenerative medicine, immunobiology, and biomedical technologies. It also summarizes some of ISMETT's research areas like adoptive immunotherapies, fetal hepatocyte transplantation, pancreatic islet transplantation, and characterization of stem/progenitor cells. Services mentioned include development of adoptive immunotherapies, stem cell production in GMP facilities, and clinical trials.
This short document provides a link to more information about deadlift dynamite on the valuesponsors.com website. Clicking the link would take the user to a page with additional details about deadlift exercises or related products/services. In a few words, it directs the reader to learn more about deadlifts online.
This document discusses bone structure and repair. It describes how bone defects like fractures require repair through tissue engineering approaches using mesenchymal stem cells (MSCs). While MSC therapy shows promise in preclinical studies, it faces challenges in clinical translation due to regulatory hurdles, remaining scientific problems, and high costs. The document also explores how implanted MSCs may trigger endogenous bone repair by stimulating macrophage migration, angiogenesis, and new bone formation. Finally, it outlines research objectives to further study the effects of microenvironments like hypoxia and inflammation on MSC paracrine activity and develop products from platelets and MSC-conditioned media for tissue repair.
The Molecular Biotechnology Center (MBC) is a research center located at the University of Torino that brings together investigators from different scientific backgrounds to facilitate interdisciplinary biomedical research. The MBC has over 200 researchers working in 6 main areas: inflammatory diseases, oncogenesis and tumor immunology, cardiac hypertrophy, stem cells, neurobiology, and bioinformatics. It provides facilities like an animal house, transgenic mouse generation, protein production, and antibody characterization to support the research.
This document describes the facilities and research at ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), a transplant hospital and research foundation in Palermo, Italy. The document outlines ISMETT's laboratories for regenerative medicine, immunobiology, and biomedical technologies. It also summarizes some of ISMETT's research areas like adoptive immunotherapies, fetal hepatocyte transplantation, pancreatic islet transplantation, and characterization of stem/progenitor cells. Services mentioned include development of adoptive immunotherapies, stem cell production in GMP facilities, and clinical trials.
This document discusses the development of biopolymer-based biomaterials for biomedical applications such as orthopedics, dentistry, and surgery. Specifically, it describes chitlac, a polysaccharide derived from chitosan that is soluble at physiological pH, miscible with anionic polysaccharides, and biocompatible. It discusses modifying chitlac's chemical structure to modulate its biological activity, such as by conjugating it with RGD peptides. The document proposes using mixtures of chitlac and alginate as a scaffold for tissue engineering and cell encapsulation. It outlines characterizing the materials' chemistry, structure, mechanics, and in vitro biological performance. Finally, it presents the AnastomoSEAL
This document describes several approaches for studying the role of the Cripto protein in muscle stem cell regeneration:
1) Cripto loss-of-function and gain-of-function mouse models to understand how changes in Cripto expression impact muscle stem cells.
2) Using mouse models of acute muscle damage to study how Cripto influences mobilization of muscle stem cells.
3) High-throughput screening to identify new regulators of muscle stem cells by analyzing gene expression changes from Cripto loss-of-function cells.
4) Developing recombinant Cripto protein and pharmacological delivery methods to promote stem cell-based muscle regeneration.
This document discusses the development of biopolymer-based biomaterials for biomedical applications such as orthopedics, dentistry, and surgery. Specifically, it describes chitlac, a polysaccharide derived from chitosan that is soluble at physiological pH, miscible with anionic polysaccharides, and biocompatible. It discusses modifying chitlac's chemical structure to modulate its biological activity, such as by conjugating it with RGD peptides. The document proposes using mixtures of chitlac and alginate as a scaffold for tissue engineering and cell encapsulation. It outlines characterizing the materials' chemistry, structure, mechanics, and in vitro biological performance. Finally, it presents the AnastomoSEAL
This document describes several approaches for studying the role of the Cripto protein in muscle stem cell regeneration:
1) Cripto loss-of-function and gain-of-function mouse models to understand how changes in Cripto expression impact muscle stem cells.
2) Using mouse models of acute muscle damage to study how Cripto influences mobilization of muscle stem cells.
3) High-throughput screening to identify new regulators of muscle stem cells by analyzing gene expression changes from Cripto loss-of-function cells.
4) Developing recombinant Cripto protein and pharmacological delivery methods to promote stem cell-based muscle regeneration.
2. LA TRIADE DELLE ADVANCED THERAPIES
SCAFFOLDS
GROW
FACTORS
CELLULE
08/07/13 2
PRODOTTI DI
INGEGNERIA
TISSUTALE
A.T. GRADE nasce per essere il partner industriale per le Banche dei Tessuti e Cellule del Sistema Sanitario
Nazionale Italiano ed Europee per la produzione in classe farmaceutica GMP di specialità medicinali per i
prodotti di ingegneria tissutale che rientrano sotto la regolamentazione europea delle Advanced Therapies
(ATMP)
3. ESPLETAMENTO GARA NIGUARDA
08/07/13 3
L’azienda ospedaliera di Niguarda nel 2008 ha espletato una gara d’appalto europea dal
titolo:
“PROCEDURA RISTRETTA PER LA SELEZIONE DI UN SOGGETTO PRIVATO CUI
AFFIDARE LA GESTIONE DEI NUOVI LABORATORI DEL CENTRO DI
RIFERIMENTO REGIONALE PER LA COLTURA DI EPIDERMIDE UMANA IN
VITRO E DELLA BANCA PER LA CRIOCONSERVAZIONE DEI TESSUTI” bandita
dall’Ospedale Niguarda di Milano
In data 9 dicembre 2008 il consorzio Cell F&B si è aggiudicato il l’appalto in oggeKo.
In data 1 aprile 2009 è stato firmato il contrato e sono iniziate le operazioni di convalida,
di autocertificazione e di produzione.
5. FIBROBLASTI
E
CHERATINOCITI
SU
SCAFFOLD
— Si
propone
la
realizzazione
di
uno
studio
di
sperimentazione
clinica
di
fase
1
e
2
,
attraverso
la
presentazione
di
un
dossier
(IMPD)
presso
le
competenti
autorità
regolatorie,
per
un
farmaco
di
ingegneria
tissutale
che
ricade
sotto
la
normativa
delle
ATMP,
basato
su
scaffolds
di
acido
ialuronico
esterificato
e
cellule
(cheratinociti
e
fibroblasti
di
origine
allogenica)
che
possano
ricreare
i
presupposti
di
microambienti
atti
alla
sopravvivenza
cellulare,
alla
migrazione
e
proliferazione
nonché
alla
liberazione
di
fattori
trofici
(es.
fattori
di
crescita
quali
KGR
e
FGF)
che
agevolino
il
processo
di
riparazione.
— Questi
prodotti
sono
indicati
per
la
cura
di
ulcere
croniche
(venose
o
diabetiche).
08/07/13 5
6. FIBROBLASTI
IN
SOSPENSIONE
— Si
propone
la
realizzazione
di
uno
studio
di
sperimentazione
clinica
di
fase
1
e
2
,
attraverso
la
presentazione
di
un
dossier
(IMPD)
presso
le
competenti
autorità
regolatorie
per
la
produzione
di
un
farmaco
di
ingegneria
tissutale
che
ricade
sotto
la
normativa
delle
ATMP,
basato
su
cellule
autologhe
espanse
in
vitro
imputate
alla
rigenerazione
del
tessuto
dermale
(fibroblasti)
e
mantenute
in
una
sospensione
(fase
liquida)
di
siero
autologo
che
agevoli
il
processo
di
riparazione.
Tale
procedura
è
atta
alla
riparazione
dei
danni
dermali
dovuti
ad
importanti
alterazioni
morfo-‐strutturali
causati
da
esiti
chirurgici
o
traumatici
o
patologie
degenerative.
08/07/13 6
7. ATTIVITA’
PREVISTE
08/07/13 7
(I) SS1: valutazione del progetto di registrazione dei farmaci e
preparazione della documentazione necessaria per le
attività di realizzazione del protocollo di studio e reclutamento
pazienti (previsti 150) ( 0-3 mesi)
(ii) SS2: start-up delle attività. Approvazione protocolli, CRF,
consensi informati, brochure, identificazione dei centri
coinvolti, approvazione dell’Autorità competente.(4-9 mesi)
(iii) RI1: inizio attività di arruolamento e valutazione, visite di
monitoraggio. Familiarizzazione strumenti a supporto
(CRF, Database, ecc…). Data Management (10-20 mesi)
(iv) RI2: Biostatistica. Preparazione piano di analisi statistica,
grafici e valutazione finale. (21-24 mesi)
(v) RI3: Redazione del Clinical Study Report e presentazione.
(25-30 mesi)
TOTALE: 30 mesi
